Core Insights - Twist Bioscience reported a strong first-quarter performance for fiscal 2026, with revenue reaching $103.7 million, reflecting a 17% year-over-year growth and marking the 12th consecutive quarter of revenue growth [5][4]. - The growth was significantly driven by demand for AI-enabled discovery, with over $25 million in orders specifically tied to this area booked for fiscal 2025 [1][5]. - The company aims for adjusted EBITDA break-even by the fourth quarter of fiscal 2026, while also increasing operating expenses to support growth [13][5]. Financial Performance - DNA synthesis and protein solutions (DSPS) revenue increased to $51.1 million, up 27% year-over-year [1]. - Adjusted EBITDA loss was approximately $13.4 million, an improvement of about $2.8 million compared to the prior-year quarter [3]. - Gross margin was reported at 52.0%, higher than expected, attributed to revenue growth and process improvements [4]. Market Trends - The company is expanding its services beyond DNA synthesis to include protein expression and antibody characterization, targeting large pharma, tech companies, and well-funded biotechs [6]. - NGS applications revenue was approximately $52.6 million, with an 18% year-over-year growth when excluding one large customer [7]. - Therapeutics revenue increased to approximately $37.2 million, up 39% year-over-year, driven by greater uptake from large pharma and biotech [15]. Guidance and Outlook - Twist raised its full-year revenue outlook to $435 million to $440 million, indicating about 16% growth at the midpoint [12]. - For the second quarter, the company expects revenue of $107 million to $108 million, also reflecting about 16% growth at the midpoint [12]. - Management expressed confidence in continued growth in NGS driven by key accounts and partnerships [9][10]. Geographic and Sector Performance - Revenue by geography showed growth in the Americas ($58.4 million), EMEA ($38.4 million), and APAC ($7.0 million) compared to the previous year [11]. - Global supply partner revenue rose to $12.8 million, a 50% increase, attributed to new partnerships and growth among diagnostics OEM partners [11]. - Academic research and government revenue remained flat at approximately $12.2 million, with expectations for growth in the second quarter due to increased confidence in NIH funding [15].

U.S. equities are showing resilience in midday trading on Monday, February 2nd, 2026, as major indexes staged a notable rebound from earlier declines. After a volatile overnight session and a soft start to the week, the market found its footing, with investors digesting a mix of corporate news, shifting commodity prices, and an eye towards a busy economic calendar ahead. The midday momentum suggests a market striving to snap a recent losing streak, driven by specific sector strength and a cautious optimism. ...

分组1 - Twist Bioscience reported a quarterly loss of $0.5 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.48, and an improvement from a loss of $0.53 per share a year ago, indicating a surprise of -5.26% [1] - The company generated revenues of $103.7 million for the quarter ended December 2025, slightly missing the Zacks Consensus Estimate by 0.05%, but showing growth from $88.71 million in the same quarter last year [2] - Over the last four quarters, Twist Bioscience has surpassed consensus revenue estimates three times, but only once for EPS estimates [2] 分组2 - The stock has increased by approximately 29.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.4% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates at -$0.46 for the coming quarter and -$1.64 for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Twist Bioscience belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Financial Data and Key Metrics Changes - Revenue for Q1 increased to $103.7 million, representing a growth of 17% year-over-year and approximately 5% sequentially [21] - Gross margin improved to 52.0%, an increase of approximately four margin points compared to Q1 of Fiscal 2025 [21][25] - Adjusted EBITDA loss was approximately $13.4 million, an improvement of about $2.8 million versus Q1 of Fiscal 2025 [25] Business Line Data and Key Metrics Changes - DNA synthesis and protein solutions revenue rose to $51.1 million, a growth of 27% year-over-year, driven by demand from customers pursuing AI-enabled discovery [21] - NGS applications revenue grew to approximately $52.6 million, with an 18% year-over-year growth when excluding one large customer [21] - Revenue from therapeutics increased to approximately $37.2 million, reflecting a 39% increase year-over-year [22] Market Data and Key Metrics Changes - Americas revenue increased to approximately $58.4 million, a growth of 9% year-over-year [22] - AMEA revenue rose to approximately $38.4 million, a growth of 36% year-over-year [22] - Global supply partner revenue increased by 50% to $12.8 million, driven by new partnerships and growth in diagnostics OEM partners [24] Company Strategy and Development Direction - The company aims to leverage its semiconductor-based DNA synthesis platform to enhance speed, scale, quality, and affordability for customers [6] - The estimated serviceable market has expanded from approximately $2 billion in 2020 to roughly $7 billion today, with expectations to exceed $12 billion by 2030 [8] - The company is focused on disciplined product innovation and expanding its addressable markets while maintaining margin discipline and capital efficiency [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in reaching Adjusted EBITDA break-even by Q4 of Fiscal 2026, supported by consistent revenue growth and disciplined investment in operating expenses [29][30] - The company is well-positioned to capitalize on the growing demand for AI-enabled drug discovery and precision diagnostics [30] - Management noted that the growth is driven by a repeatable model and operational execution that scales efficiently [28] Other Important Information - The company plans to host an investor day in May to provide deeper insights into its strategy, product roadmap, and market expansion opportunities [30] - The company has made targeted investments in commercial teams and digital infrastructure to support growth [11][52] Q&A Session Summary Question: Demand for AI-driven discovery and its duration - Management noted that demand is expected to be durable, with customers returning for larger orders and the potential for AI to become the first pass in drug discovery [34] Question: Increased guidance confidence for DNA synthesis and NGS - Management indicated that confidence comes from overall strong performance across the board, with a specific customer dynamic in NGS applications having improved [39] Question: Gross margin expectations for Q2 and beyond - Management expects continued improvements in gross margin throughout the year, but at a moderated pace due to ongoing investments in capacity and automation [48] Question: Strategic investments made in the quarter - Investments were made in hiring sales and commercial personnel, as well as transient investments in digital infrastructure to enhance e-commerce capabilities [52] Question: New partnerships in the diagnostic space - Management is actively working on securing new partnerships for sustained growth in 2027 and beyond, while current growth in 2026 will primarily come from existing partners [58]

Twist Bioscience (NasdaqGS:TWST) Q1 2026 Earnings call February 02, 2026 08:00 AM ET Company ParticipantsAdam Laponis - CFOAngela Bitting - SVP of Corporate AffairsDoug Schenkel - Managing DirectorEmily Leproust - CEO and Co-FounderMac Etoch - Research AssociateMatt Larew - PartnerPatrick Finn - President and COOSubbu Nambi - Managing DirectorConference Call ParticipantsBrendan Smith - Health Care AnalystNone - AnalystNone - AnalystOperatorLadies and gentlemen, thank you for standing by. Welcome to Twist Bi ...

Financial Data and Key Metrics Changes - Revenue for Q1 increased to $103.7 million, representing a 17% year-over-year growth and approximately 5% sequentially [20] - Gross margin improved to 52.0%, an increase of approximately four margin points compared to Q1 of Fiscal 2025 [20][24] - Adjusted EBITDA loss was approximately $13.4 million, an improvement of about $2.8 million versus Q1 of Fiscal 2025 [24] Business Line Data and Key Metrics Changes - DNA synthesis and protein solutions revenue rose to $51.1 million, a 27% year-over-year increase driven by AI-enabled discovery [20] - NGS applications revenue grew to approximately $52.6 million, with an 18% year-over-year growth when excluding one large customer [20] - Revenue from therapeutics increased to approximately $37.2 million, reflecting a 39% year-over-year growth [21] Market Data and Key Metrics Changes - Americas revenue increased to approximately $58.4 million, a 9% year-over-year growth [21] - AMEA revenue rose to approximately $38.4 million, a 36% year-over-year increase [21] - APAC revenue increased to approximately $7 million, compared to $6.7 million in the same period of Fiscal 2025 [21] Company Strategy and Development Direction - The company aims to leverage its semiconductor-based DNA synthesis platform to enhance speed, scale, quality, and affordability for customers [5] - The estimated serviceable market has expanded from approximately $2 billion in 2020 to roughly $7 billion today, with a target of over $12 billion by 2030 [7][8] - The company is focused on disciplined product innovation and expanding its addressable markets while maintaining margin discipline [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in reaching Adjusted EBITDA break-even by Q4 of Fiscal 2026, supported by consistent revenue growth and disciplined investment in operating expenses [11][27] - The company sees a durable opportunity in AI-enabled discovery, with increasing orders from large pharma and biotech customers [31][49] - Management highlighted the importance of maintaining a scalable cost structure while investing in growth [12][27] Other Important Information - The company plans to host an investor day in May to provide deeper insights into its strategy, product roadmap, and market expansion opportunities [28] - The company ended the quarter with $197.9 million in cash, cash equivalents, and short-term investments [25] Q&A Session Summary Question: Demand for AI-driven discovery and its duration - Management noted that demand is expected to be durable, with customers returning for larger orders, indicating strong growth potential [31] Question: Increased guidance confidence for DNA synthesis and NGS - Management attributed increased confidence to overall strong performance across the board and the return of a previously mentioned customer [37] Question: Gross margin expectations for Q2 and beyond - Management indicated that while gross margin improvements are expected, investments in growth may moderate the pace of margin expansion [44][46] Question: Strategic investments made in the quarter - Management detailed structural investments in hiring sales personnel and transient investments in digital infrastructure to support growth [50][52] Question: New partnerships in the diagnostic space - Management confirmed that growth in NGS for FY 2026 will primarily come from existing partners, with new partnerships being crucial for sustained growth in 2027 and beyond [56]

Fiscal 2026 Q1 Financial Results F E B R U A R Y 2 0 2 6 Legal Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, projections under the heading "FY 2026 Guidance", statements regarding future growth and expans ...

Revenue Results - Twist Bioscience Corporation announced preliminary, unaudited revenue results for Q1 fiscal 2026, ending December 31, 2025[4]. - The revenue expectations are subject to change based on ongoing internal control, review, and audit procedures, indicating potential material differences from final financial statements[5]. - The press release detailing the preliminary revenue results is dated January 12, 2026, and is available as Exhibit 99.1[8].

Core Viewpoint - Twist Bioscience Corporation announced its financial results and business highlights for the first quarter of fiscal 2026, which ended on December 31, 2025 [1]. Financial Results - The detailed fiscal first quarter 2026 earnings report and investor presentation are available on the company's Investor Relations page [2]. Conference Call - The company will hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss financial results and provide business updates [3]. Company Overview - Twist Bioscience focuses on serving customers in various fields such as medicine, agriculture, industrial chemicals, and defense, utilizing synthetic DNA tools to improve lives and sustainability [4]. Technology Platform - The company offers an innovative silicon-based DNA Synthesis Platform that provides precision at an unprecedented scale, enabling cost-effective and rapid synthesis, sequencing, and therapeutics discovery [5].

Core Viewpoint - Twist Bioscience (TWST) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on February 2, with a consensus estimate of a quarterly loss of $0.48 per share, reflecting a year-over-year change of +9.4% [3][11]. - Revenues are projected to reach $101.45 million, which is a 14.4% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial estimates during this period [4]. - The Most Accurate Estimate for Twist Bioscience is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.05%, suggesting a bearish outlook from analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from the consensus estimate, with positive readings being more reliable [8][9]. - Twist Bioscience currently holds a Zacks Rank of 2 (Buy), but the negative Earnings ESP complicates predictions of an earnings beat [11]. Historical Performance - In the last reported quarter, Twist Bioscience was expected to post a loss of $0.40 per share but actually reported a loss of $0.45, resulting in a surprise of -12.50% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [13]. Industry Comparison - Regeneron (REGN), another player in the biomedical and genetics industry, is expected to report earnings of $10.6 per share for the same quarter, indicating a year-over-year change of -12.2% and revenues of $3.82 billion, up 0.7% from the previous year [17][18]. - Regeneron has an Earnings ESP of +1.06% and a Zacks Rank of 1 (Strong Buy), suggesting a higher likelihood of beating the consensus EPS estimate [19].